[{"name": "PERINEAL TALC EXPOSURE AND EPITHELIAL OVARIAN CANCER RISK IN THE CENTRAL VALLEY OF CALIFORNIA", "features": [[{"name": "Conclusion", "value": "This study provides some support for the\nhypothesis that perineal talc use is associated with an in-\ncreased risk of EOC.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "256 cases diagnosed in the years 2000\u20132001 and 1,122 controls", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "OR for ever use of talc was 1.37 (CI (cid:1) 1.02\u20131.85) compared to never users", "mandatory": true, "score": 0.8}, {"name": "Length of Follow", "value": null, "mandatory": true, "score": 0.5}, {"name": "Key Words", "value": "epidemiology; gynecologic cancer; risk factors", "mandatory": false, "score": 0.7}, {"name": "Demographics", "value": "Central California, which is the poorest area of the state, with many residents living below the poverty level", "mandatory": false, "score": 0.6}, {"name": "Ethnic Diversity", "value": "Valley is a very ethnically diverse area in which many counties are over 40% Hispanic.", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "Talcum Powder use in the genital area may increase the risk of developing ovarian cancer", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "635 cases", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "Age-adjusted and multivariate-adjusted odds ratios", "mandatory": true, "score": 0.7}, {"name": "Length of Follow", "value": "2-year period", "mandatory": true, "score": 0.6}, {"name": "Histologic subtypes", "value": "Serous, mucinous, endometrioid, clear cell and other epithelial/unclassified", "mandatory": false, "score": 0.5}, {"name": "Grant Sponsor", "value": "California Cancer Research Program", "mandatory": false, "score": 0.4}, {"name": "Pathology review", "value": "A board-certified pathologist reviewed the pathology reports of a sample of cases", "mandatory": false, "score": 0.3}], [{"name": "Conclusion", "value": "42.6% of EOC cases reported ever use of talcum powder in the perineal area while 37.1% of control women reported such a history.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "256 completed interviews for cases and 1,122 completed control interviews.", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": null, "mandatory": true, "score": 0.5}, {"name": "Length of Follow", "value": null, "mandatory": true, "score": 0.5}, {"name": "Invasiveness", "value": "Invasive tumors constituted 71.1% of the case series and 28.9% of the tumors were of borderline malignancy.", "mandatory": false, "score": 0.4}, {"name": "Histologic subtypes", "value": "57% of the case series were serous adenocarcinomas, divided 60% and 40% for invasive and borderline, respectively. Mucinous and endometrioid each comprised 14% of the EOC cases.", "mandatory": false, "score": 0.4}, {"name": "Education Level", "value": "Control women were less likely to have finished high school but more likely to have an education beyond high school.", "mandatory": false, "score": 0.3}], [{"name": "Conclusion", "value": "Ever use of talcum powder in the genital area was associated with a 37% elevation in risk of EOC, which was statistically significant", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "256 cases and 1,122 controls", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "1.37 (1.02\u20131.85)", "mandatory": true, "score": 0.8}, {"name": "Length of Follow", "value": "Not mentioned", "mandatory": true, "score": 0.7}, {"name": "Histologic Subtype", "value": "Elevated odds ratios were primarily among those with a serous or mucinous invasive tumor", "mandatory": false, "score": 0.6}, {"name": "Timing of Use", "value": "There were multiple categories based on timing of talc use", "mandatory": false, "score": 0.5}, {"name": "Categorization of Talc Use", "value": "There were multiple categories based on frequency, intensity, and duration of talc use", "mandatory": false, "score": 0.5}], [{"name": "Conclusion", "value": "The study found that higher risk of EOC was associated with the use of talcum powder. The highest and significant risks were found among women who had stopped using talcum powder relatively recently (1-2 years prior to interview). Women without a tubal ligation experienced higher talcum powder-associated risks than women with a tubal ligation and this result was statistically significant (OR 1.54; 95% CI 1.10-2.16). The interaction coefficient for the relationship between talc use and tubal ligation was not statistically significant. Neither BMI nor hormone replacement therapy use appeared to modify the relationship of talc use and EOC risk.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": "Cases (n=256), Controls (n=1,122)", "mandatory": true, "score": 0.7}, {"name": "Relative risk", "value": "Multiple multivariate-adjusted odds ratios were presented for different variables. The highest relative risk was associated with talcum powder use among women who had stopped using it relatively recently, with an OR of 4.91 (95% CI 0.68-35.25) for no HRT use. The association of talcum powder use and EOC risk was statistically significant among women without a tubal ligation (OR 1.54; 95% CI 1.10-2.16), but the interaction coefficient for the relationship between talc use and tubal ligation was not statistically significant.", "mandatory": true, "score": 0.8}, {"name": "Length of follow", "value": "Not provided in the text", "mandatory": true, "score": 0.2}, {"name": "Race/ethnicity", "value": "Not specifically discussed, but may have been included as a variable in the multivariate analysis", "mandatory": false, "score": 0.4}, {"name": "Reproductive history", "value": "The study found that higher risks were observed among those who were ever pregnant compared to those who were never pregnant. Talcum powder-associated risk was not different within the parous and nulliparous.", "mandatory": false, "score": 0.6}, {"name": "Age", "value": "Not specifically discussed as a variable, but some information on talc use patterns among different age groups was mentioned", "mandatory": false, "score": 0.3}], [{"name": "Conclusion", "value": "Talc use was found to contribute to the increased risk of EOC among talc users. No relationship exists between cornstarch and EOC. Talc use and EOC risk varied by histologic subtype and age at first use. Use of talc products after 1975 was associated with an increased risk of EOC.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": null, "mandatory": true, "score": 0.5}, {"name": "Relative risk", "value": "OR (cid:1) 1.37; CI (cid:1) 1.02\u20131.85", "mandatory": true, "score": 0.8}, {"name": "Length of follow", "value": null, "mandatory": true, "score": 0.6}, {"name": "Ethnicity", "value": "Talc use was higher in white non-Hispanics compared to Hispanics in this study. There was much greater use of talc among those born in the United States versus those born outside of it.", "mandatory": false, "score": 0.6}, {"name": "Education level", "value": "As in other studies, talc use increased with education level.", "mandatory": false, "score": 0.5}, {"name": "Marital status", "value": "Talc exposure was 43.8% for ever married cases versus 34.4% for never married cases. Frequency of use was similar between ever married and never married controls.", "mandatory": false, "score": 0.5}], [{"name": "Conclusion", "value": "Perineal talc use after first birth increases the risk of developing EOC", "mandatory": true, "score": 1}, {"name": "No. of Subjects", "value": "N/A", "mandatory": true, "score": 0.5}, {"name": "Relative Risk", "value": "N/A", "mandatory": true, "score": 0.5}, {"name": "Length of Follow", "value": "N/A", "mandatory": true, "score": 0.5}, {"name": "Impact on EOC Risk Among Nulliparous Women", "value": "N/A", "mandatory": false, "score": 0.7}, {"name": "Effect of Oral Contraceptives on Talc Use and EOC Risk", "value": "Talcum powder users who never used OCs had elevated EOC risk", "mandatory": false, "score": 0.8}, {"name": "BMI as a Confounder of Talc Use and EOC Risk", "value": "BMI did not modify the risk associated with talc use and EOC", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "Research has provided little biologic or experimental evidence to support a relationship between talcum powder use and ovarian cancer risk. However, given the suggestive though uncertain role of talcum powder and EOC found in epidemiologic studies, including the present study, users should exercise prudence in reducing or eliminating use. In this instance, the precautionary principle should be invoked, especially given that this is a serious form of cancer, usually associated with a poor prognosis, with no current effective screening tool, steady incidence rates during the last quarter century and no prospect for successful therapy. Unlike other forms of environmental exposures, talcum powder use is easily avoidable.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": null, "mandatory": true, "score": 0.0}, {"name": "Relative Risk", "value": null, "mandatory": true, "score": 0.0}, {"name": "Length of Follow", "value": null, "mandatory": true, "score": 0.0}, {"name": "Inability to exclude use during nonovulatory periods", "value": "due to our inability to exclude use during nonovulatory periods", "mandatory": false, "score": 0.7}, {"name": "Inability to exclude posttubal ligation or hysterectomy", "value": "nor were we able to differentiate between various formulations", "mandatory": false, "score": 0.7}, {"name": "Perineal application of talcum powder and risk of EOC", "value": "Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies.", "mandatory": false, "score": 0.8}], [{"name": "Conclusion", "value": "The paper discusses various studies on the link between ovarian cancer and exposure to substances such as talcum powder and asbestos. The studies suggest a possible decreased risk of ovarian cancer with tubal sterilization and hysterectomy. The link between perineal talc exposure and ovarian cancer is not yet fully understood.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": null, "mandatory": true, "score": 0.5}, {"name": "Relative Risk", "value": null, "mandatory": true, "score": 0.5}, {"name": "Length of Follow", "value": "40 years", "mandatory": true, "score": 0.7}, {"name": "Ovarian epithelial inflammation", "value": "Possible role in ovarian cancer", "mandatory": false, "score": 0.6}, {"name": "Talc exposure", "value": "Link to ovarian cancer not fully understood", "mandatory": false, "score": 0.6}, {"name": "Substances linked to epithelial ovarian cancer", "value": "Talcum powder, tobacco, alcohol, and coffee", "mandatory": false, "score": 0.7}]]}, {"name": "Perineal talc exposure and risk of ovarian carcinoma", "features": [[{"name": "Conclusion", "value": "This investigation supports previous contentions that exposure to talc may increase risk of ovarian carcinoma. Questionable trends in duration and frequency of exposure suggest that further studies may be needed to clarify the role of talc in the etiology of this disease.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "450 patients with borderline and invasive ovarian carcinoma and 564 population controls in metropolitan Toronto and nearby areas of southern Ontario, Canada", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "OR 1.42, 95% confidence interval [CI] 1.08\u20131.86", "mandatory": true, "score": 0.8}, {"name": "Length of follow", "value": null, "mandatory": true, "score": 0.5}, {"name": "Risk Factors Considered", "value": "sanitary napkin usage, direct application to the perineum", "mandatory": false, "score": 0.6}, {"name": "Location of Study", "value": "metropolitan Toronto and nearby areas of southern Ontario, Canada", "mandatory": false, "score": 0.5}, {"name": "Type of Cancer", "value": "ovarian carcinoma", "mandatory": false, "score": 0.4}], [{"name": "Conclusion", "value": "Women with regular talc exposure were at an increased risk of ovarian carcinoma.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "450 ovarian carcinoma cases and 564 population controls", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "OR 1.42, 95% confidence interval [CI] 1.08 \u2013 1.86", "mandatory": true, "score": 0.9}, {"name": "Length of Follow-Up", "value": "Not specified", "mandatory": true, "score": 0.5}, {"name": "Dusting Behaviors", "value": "Exposure to talc via sanitary napkins had a nonsignificant increase in odds (OR 1.26, 95% CI 0.81 \u2013 1.96)", "mandatory": false, "score": 0.6}, {"name": "Medical and Reproductive Histories", "value": "Questionnaire administered during in-person, in-home interview after informed consent was obtained. Focused on menstrual characteristics, pregnancies, hormone and contraceptive use, talc and cornstarch usage.", "mandatory": false, "score": 0.7}, {"name": "Modeling Method", "value": "Multiple unconditional logistic regression with the SAS statistical package", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "There is a possible association between talc exposure and ovarian carcinoma", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": null, "mandatory": true, "score": 0.4}, {"name": "Relative Risk", "value": "OR 1.31, 95% CI 1.00 \u2013 1.73; OR per 10 years of use 1.06, 95% CI 0.99 \u2013 1.14", "mandatory": true, "score": 0.8}, {"name": "Length of Follow", "value": null, "mandatory": true, "score": 0.4}, {"name": "Mean years of after-bath talc use", "value": "32.9 for cases who had ever used talc after bathing and 35.4 for controls", "mandatory": false, "score": 0.7}, {"name": "Duration of after-bath talc use", "value": "durations of less than 30 years of talc use showed increased risk, relative to no talc exposure", "mandatory": false, "score": 0.6}, {"name": "Frequency of talc use", "value": "frequencies of less than 10 applications per month may be associated with increased risk", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "Greater risk was associated with any regular talc exposure (OR 1.42, 95% CI 1.08 \u2013 1.86).", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": null, "mandatory": true, "score": 0.0}, {"name": "Relative risk", "value": "1.42", "mandatory": true, "score": 0.8}, {"name": "Length of follow", "value": null, "mandatory": true, "score": 0.0}, {"name": "Primary mode of talc exposure", "value": "Direct application to the perineum", "mandatory": false, "score": 0.6}, {"name": "Dose-response relationship", "value": "A questionable dose-response relationship was observed between duration or frequency of exposure and risk. Duration as a continuous variable indicated that risk may increase with increasing years of talc exposure.", "mandatory": false, "score": 0.7}, {"name": "Association between talc usage and ovarian carcinoma", "value": "Several lines of evidence support the argument for an association between talc usage and ovarian carcinoma.", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "The results of this study appear to support the contention that talc exposure increases risk of ovarian carcinoma.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": null, "mandatory": true, "score": 0.5}, {"name": "Relative Risk", "value": null, "mandatory": true, "score": 0.5}, {"name": "Length of follow", "value": null, "mandatory": true, "score": 0.5}, {"name": "Strengths and weaknesses of study discussed", "value": true, "mandatory": false, "score": 0.7}, {"name": "Relevance to heterogeneity of ovarian carcinoma", "value": true, "mandatory": false, "score": 0.6}, {"name": "Further studies required", "value": true, "mandatory": false, "score": 0.6}]]}, {"name": "The Association Between Talc Use and Ovarian Cancer", "features": [[{"name": "Conclusion", "value": "risks for epithelial ovarian cancer from genital talc use vary by histologic subtype, menopausal status at diagnosis, Ht use, weight, and smoking. these observations suggest that estrogen and/or prolactin may play a role via macrophage activity and inflammatory response to talc.", "mandatory": true, "score": 1}, {"name": "No. of subjects", "value": "2,041 cases with epithelial ovarian cancer and 2,100 age- and-residence-matched controls", "mandatory": true, "score": 1}, {"name": "Relative risk", "value": "1.33 (1.16, 1.52)", "mandatory": true, "score": 1}, {"name": "Length of follow", "value": null, "mandatory": true, "score": 1}, {"name": "Trends for increasing risk by talc-years", "value": null, "mandatory": false, "score": 0.8}, {"name": "Association more apparent for premenopausal women, especially nonsmokers and those heavier or postmenopausal users of menopausal hormones", "value": null, "mandatory": false, "score": 0.7}, {"name": "More likely to be associated with talc: invasive serous and endometrioid tumors and borderline serous and mucinous tumors", "value": null, "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "Genital use of talc was associated with an Or (95% ci) of 1.33 (1.16, 1.52) adjusted only for age, study center, and phase.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": "2,041 cases and 1,578 controls", "mandatory": true, "score": 0.8}, {"name": "Relative risk", "value": "1.33", "mandatory": true, "score": 0.8}, {"name": "Length of follow", "value": "not provided", "mandatory": true, "score": 0.5}, {"name": "Powder type", "value": "Johnson & Johnson's Baby Powder or Shower to Shower", "mandatory": false, "score": 0.6}, {"name": "Talc applied frequency", "value": "trend for frequency of use was significant", "mandatory": false, "score": 0.6}, {"name": "Personal genital talc exposure", "value": "subjects were classified as ever-users if they had personal genital talc exposure", "mandatory": false, "score": 0.5}], [{"name": "Conclusion", "value": "An OR of 1.49 (95% ci = 1.06, 2.10) was associated with more than 20 talc-years (>7,200 applications) and a dose-response.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": "Cases: 449, Controls: 1551", "mandatory": true, "score": 0.7}, {"name": "Relative risk", "value": "OR of 1.49 (95% ci = 1.06, 2.10)", "mandatory": true, "score": 0.8}, {"name": "Length of follow-up", "value": "Not provided", "mandatory": true, "score": 0.5}, {"name": "Type of powder used", "value": "Cornstarch use only, Johnson and Johnson Baby Powder or Shower to Shower, Other brand(s)", "mandatory": false, "score": 0.6}, {"name": "Frequency of powder use", "value": "1\u20137 days per month, 8\u201329 days per month, \u226530 days per month", "mandatory": false, "score": 0.6}, {"name": "Age at first powder use", "value": "Never used, <20, 20\u201329, \u226530", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "There is an association between genital use of talc and epithelial ovarian cancer.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": "1,551 (Controls) and 1,399 (Cases)", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "1.33 (95% CI: 1.16-1.53)", "mandatory": true, "score": 0.9}, {"name": "Length of follow", "value": "Not Specified", "mandatory": true, "score": 0.5}, {"name": "Asthma Sufferers", "value": "More likely to be powder users.", "mandatory": false, "score": 0.6}, {"name": "Age", "value": "Powder users, both cases and controls, were more likely to be older.", "mandatory": false, "score": 0.6}, {"name": "Body Mass Index", "value": "Heavier powder users had higher likelihood of ovarian cancer.", "mandatory": false, "score": 0.7}], [{"name": "Conclusion", "value": "Increased epithelial ovarian cancer risk with talc use on genitals was found, with the risk being higher for serous and endometrioid invasive and serous borderline tumors, especially in premenopausal women.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": null, "mandatory": true, "score": 0.7}, {"name": "Relative Risk", "value": "1.33 (1.16, 1.52)", "mandatory": true, "score": 0.8}, {"name": "Length of Follow", "value": null, "mandatory": true, "score": 0.6}, {"name": "Interaction with Menopausal Status", "value": "Figure 2 suggests that eOc risk with talc varies by menopausal status, with increased risk in premenopausal women who used talc before the procedure, and elevated risk for use both before and after the procedure in postmenopausal women who used Ht. Categories for several variables revealed contrasting overall associations and/or clearer dose\u2013responses for both pre- and post-menopausal women who were least likely to have a genetic basis for their ovarian cancer.", "mandatory": false, "score": 0.7}, {"name": "Incidence of Tumors by Histologic Subtype", "value": "Overall, talc use increased risk for serous and endometrioid invasive and serous borderline tumors, with the dose\u2013response most apparent for serous invasive cancer. For premenopausal women, both the overall associations and dose\u2013responses were stronger with serous invasive and serous borderline tumors. Pre-menopausal women also had an increased risk for mucinous borderline tumors at the highest quartile of talc use.", "mandatory": false, "score": 0.6}, {"name": "Variables adjusted for", "value": "Reference age, study center, and study phase were adjusted for all variables. BMI, height, weight, and ovulatory cycles were adjusted for with indicators for quartiles and parity (nulliparous, 1, 2, \u22652), breastfeeding (never, <4, 4\u20139, 10\u201319, >19 months), and OC use (never, <23, 23\u201349, 50\u201396, >96 months) were adjusted for with indicators for categories. Family history of ovarian or early onset breast cancer in a mother or sister was adjusted for.", "mandatory": false, "score": 0.5}], [{"name": "Conclusion", "value": "Talc use in genital area associated with 33% increase in ovarian cancer risk overall", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "N/A", "mandatory": true, "score": 1}, {"name": "Relative Risk", "value": "2.33 (premenopausal women with relevant subtypes) and 2.57 (postmenopausal Ht-users with relevant subtypes)", "mandatory": true, "score": 0.8}, {"name": "Length of Follow", "value": "N/A", "mandatory": true, "score": 1}, {"name": "Association with Clear Cell or Mucinous Invasive Epithelial Ovarian Cancer", "value": "Not associated", "mandatory": false, "score": 0.5}, {"name": "Association with Use of Powder on Genitals", "value": "24% increased risk", "mandatory": false, "score": 0.6}, {"name": "Effect Modifier in Premenopausal Women", "value": "Talc-years", "mandatory": false, "score": 0.4}], [{"name": "Conclusion", "value": "There is an association between genital talc use and ovarian cancer.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "1,861", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "1.42", "mandatory": true, "score": 0.7}, {"name": "Length of Follow", "value": "not provided", "mandatory": true, "score": 0.5}, {"name": "Genital Talc Use", "value": "Quartiles of talc-years", "mandatory": false, "score": 0.4}, {"name": "Menopausal Status", "value": "Premenopausal; Postmenopausal, Never Used HT; Postmenopausal, Ever Used HT", "mandatory": false, "score": 0.3}, {"name": "Adjusted OR (95% CI)", "value": "multiple values", "mandatory": false, "score": 0.2}], [{"name": "Conclusion", "value": "There is evidence of association between use of talc on genitals and ovarian cancer risk in the study.", "mandatory": true, "score": 0.8}, {"name": "No. of subjects", "value": "Not explicitly mentioned.", "mandatory": true, "score": 0.5}, {"name": "Relative Risk", "value": "Not explicitly mentioned.", "mandatory": true, "score": 0.5}, {"name": "Length of Follow", "value": "Not explicitly mentioned.", "mandatory": true, "score": 0.5}, {"name": "Effect Modification", "value": "The association between talc and epithelial ovarian cancer was greater in women with no personal history of breast cancer, those who had a tubal ligation or hysterectomy, in premenopausal women, and postmenopausal women who had used Ht.", "mandatory": false, "score": 0.7}, {"name": "Asthma", "value": "Talc users, both case and control subjects, were more likely to have asthma.", "mandatory": false, "score": 0.6}, {"name": "Confounding", "value": "None of the variables in table 2 altered the overall association by more than 10%, providing no indication of confounding.", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "Overall, there is an association between genital talc use and eOc and a significant trend with increasing \u201ctalc-years\u201d of use.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": null, "mandatory": true, "score": 0.4}, {"name": "Relative Risk", "value": null, "mandatory": true, "score": 0.4}, {"name": "Length of Follow", "value": null, "mandatory": true, "score": 0.4}, {"name": "Histologic Subtypes", "value": "Serous and mucinous borderline tumors and invasive serous and endometrioid tumors.", "mandatory": false, "score": 0.6}, {"name": "Medical History of Asthma", "value": "Talc users, both cases and controls, were more likely to report a medical history of asthma.", "mandatory": false, "score": 0.5}, {"name": "Potential Effect Modifiers", "value": "Premenopausal women with a greater BMI, had breastfed, were not current smokers, and consumed alcohol.", "mandatory": false, "score": 0.7}], [{"name": "Conclusion", "value": "We believe these appraisals understate the epidemiologic evidence. There have been dozens of case\u2013control studies and several have, in fact, found a dose\u2013response. The editorial further notes that \u201cit does not seem likely that additional conventional epidemiologic studies will strengthen the evidence for or against talc carcinogenicity\u201d (page 2). We believe the observations made here present a good case for talc carcinogenicity and that reanalyses of existing data from already published studies might provide confirmatory evidence.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "", "mandatory": true, "score": 0.3}, {"name": "Relative Risk", "value": "", "mandatory": true, "score": 0.3}, {"name": "Length of Follow", "value": "", "mandatory": true, "score": 0.3}, {"name": "Type of Study", "value": "Case-control Studies", "mandatory": false, "score": 0.7}, {"name": "Risk Factors", "value": "Perineal Talc Exposure", "mandatory": false, "score": 0.6}, {"name": "Data Sharing", "value": "Provided the \u201craw\u201d and derived variables examined in our study to NCIDBGap as well as the SAS and Stata programs used in this analysis.", "mandatory": false, "score": 0.8}], [{"name": "Conclusion", "value": "This text does not include any explicit conclusion", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "This text does not include any explicit data regarding the number of subjects", "mandatory": true, "score": 0.9}, {"name": "Relative Risk", "value": "This text does not include any explicit data regarding relative risk", "mandatory": true, "score": 0.9}, {"name": "Length of Follow", "value": "This text does not include any explicit data regarding length of follow", "mandatory": true, "score": 0.9}, {"name": "Author", "value": "Cramer et al.", "mandatory": false, "score": 0.7}, {"name": "Publication", "value": "Epidemiology\u2002 \u2022\u2002 Volume\u200227,\u2002Number\u20023,\u2002May\u20022016", "mandatory": false, "score": 0.7}, {"name": "Cancer Type", "value": "The text mentions ovarian cancer", "mandatory": false, "score": 0.7}]]}, {"name": "Risk factors for ovarian cancer a case-control study", "features": [[{"name": "Conclusion", "value": "High gravidity, hysterectomy, female sterilisation and oral contraceptive use were associated with a reduced risk of ovarian cancer. Infertility and late age at menopause were associated with an increase in risk.", "mandatory": true, "score": 1.0}, {"name": "No. of Subjects", "value": "235 cases and 451 controls", "mandatory": true, "score": 1.0}, {"name": "Relative Risk", "value": null, "mandatory": true, "score": 1.0}, {"name": "Length of Follow", "value": "Between October 1978 and February 1983", "mandatory": true, "score": 1.0}, {"name": "Reproductive and menstrual history", "value": null, "mandatory": false, "score": 0.7}, {"name": "Age distribution of the controls", "value": "approximately the same as that of the cases", "mandatory": false, "score": 0.5}, {"name": "Possible aetiological agents", "value": "exposure to various substances such as exogenous oestrogens, cigarettes and talc", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "Increased duration of unprotected intercourse and nulligravidity are risk factors for ovarian cancer", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "453 (235 cases and 218 controls)", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "RR=1.7 (95% CI 1.1-2.6) for nulligravid women compared to gravid women", "mandatory": true, "score": 0.8}, {"name": "Length of Follow-Up", "value": "Not explicitly mentioned in the text", "mandatory": true, "score": 0.5}, {"name": "Exposure", "value": "Duration of unprotected intercourse", "mandatory": false, "score": 0.7}, {"name": "Other Risk Factors", "value": "Number of pregnancies, age at first pregnancy/live birth, duration of lactation, history of infertility/subfertility, social class", "mandatory": false, "score": 0.6}, {"name": "Statistical Methods", "value": "Multiple logistic regression techniques using the GLIM statistical package", "mandatory": false, "score": 0.5}], [{"name": "Conclusion", "value": "Nulligravid women who had never used any method of contraception had about twice the risk of ovarian cancer compared to all other sexually active women. Ever having used oral contraception and having been sterilised were associated with a statistically significantly reduced risk of ovarian cancer, while no method was associated with a significantly elevated risk.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": null, "mandatory": true, "score": 0.5}, {"name": "Relative Risk", "value": "0.86 (0.78-0.94) associated with each pregnancy in gravid women only, 0.84 (0.75-0.94) associated with each birth in parous women only, 1.0 (0.5-1.5) associated with incomplete pregnancy in gravid women only, 1.0o associated with nulligravid women who have never used contraception", "mandatory": true, "score": 0.8}, {"name": "Length of follow-up", "value": null, "mandatory": true, "score": 0.3}, {"name": "Specific methods of contraception studied", "value": "Ever having used oral contraception and having been sterilised were associated with a statistically significantly reduced risk of ovarian cancer, while no method was associated with a significantly elevated risk.", "mandatory": false, "score": 0.7}, {"name": "Risk associated with age at natural menopause", "value": "Risk increased the later the age at natural menopause (X2 (trend) = 7.1, P < 0.01). Women having their menopause at the age of 50 years or later had nearly three times the risk of women who were menopausal before the age of 45 years.", "mandatory": false, "score": 0.6}, {"name": "Risk associated with age at first pregnancy", "value": "No data provided.", "mandatory": false, "score": 0.2}], [{"name": "Conclusion", "value": "Reproductive factors such as gravidity, duration of unprotected intercourse, use of oral contraception, having been sterilised, age at natural menopause and having had a hysterectomy were found to be statistically significantly related to ovarian cancer risk, suggesting that each may be independently associated with the risk of developing ovarian cancer.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": "Cases: 97, Controls: 197", "mandatory": true, "score": 0.7}, {"name": "Relative risk", "value": "1.0a", "mandatory": true, "score": 0.8}, {"name": "Length of follow", "value": null, "mandatory": true, "score": 0.5}, {"name": "Duration of OC use (years)", "value": "<5, 5-10, >10", "mandatory": false, "score": 0.4}, {"name": "Age at first OC use (years)", "value": "<25, 25-29, 30-34, >35", "mandatory": false, "score": 0.3}, {"name": "Total duration of ovulation", "value": null, "mandatory": false, "score": 0.2}], [{"name": "Conclusion", "value": "Nulligravid women have an increased risk of ovarian cancer. The greater the number of incomplete pregnancies the lower the risk, although the trend was not significant. Infertility is a risk factor for ovarian cancer. Women who had not conceived but had been sexually active for more than 10 years without using contraception had about six times the risk of all other women. Age at first pregnancy was not found to be associated with ovarian cancer risk although women having a first pregnancy after the age of 35 years had a higher risk compared to women having a first pregnancy at earlier ages and to nulligravid women.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": "Cases: 220, Controls: 370", "mandatory": true, "score": 0.8}, {"name": "Relative risk", "value": "RR (95% CI) 1.Oa, 0.9 (0.4-2.1), 0.2 (0.1-0.4), 0.4 (0.1-1.1), 1.0, 2.0, 2.1, 1.9, 0.9 (0.6-0.7), 1.0, 1.1, 0.9, 0.6, 4.3, 5.0, 0.7, 0.5, 1.5, 1.3, 0.7-2.3, 1.2, 0.8-2.0, 0.6, 0.02-1.1, 1.9, 2.6, (0.9-2.6), (0.7-2.0), (1.3 -3.4), (0.8-1.9)", "mandatory": true, "score": 0.9}, {"name": "Length of follow", "value": "Not found", "mandatory": true, "score": 0.3}, {"name": "Relative risks adjusted", "value": "Relative risks adjusted for age and social class.", "mandatory": false, "score": 0.5}, {"name": "Factors related to ovarian cancer", "value": "Graviditybc, unprotected intercourse (months)b, oral contraceptive useb, ever sterilizedb, age at natural menopaused, hysterectomyb", "mandatory": false, "score": 0.4}, {"name": "Talc use in genital area", "value": "Reported frequency of talc useb- Never, Rarely, Monthly, Weekly, Daily", "mandatory": false, "score": 0.3}], [{"name": "Conclusion", "value": "No overall relationship between hormone replacement therapy and ovarian cancer", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": null, "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "3.9", "mandatory": true, "score": 0.7}, {"name": "Length of Follow", "value": null, "mandatory": true, "score": 0.6}, {"name": "Use of Oral Contraceptives", "value": "Associated with a significant reduction in risk and protective effect persists after use is stopped", "mandatory": false, "score": 0.8}, {"name": "Duration of ovulation", "value": "Risk increased the longer the duration of ovulation", "mandatory": false, "score": 0.7}, {"name": "Breastfeeding", "value": "No evidence that longer a woman had breastfed lowers her risk of ovarian cancer", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "Further work is needed on the relation between genital use of talc and ovarian cancer.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "N/A", "mandatory": true, "score": 0.7}, {"name": "Relative Risk", "value": "N/A", "mandatory": true, "score": 0.7}, {"name": "Length of Follow", "value": "N/A", "mandatory": true, "score": 0.7}, {"name": "Risk Factors", "value": "Genital use of talc, reproductive and menstrual events, oral contraceptive use, age at first birth", "mandatory": false, "score": 0.8}, {"name": "Funding", "value": "Imperial Cancer Research Fund, Medical Research Council", "mandatory": false, "score": 0.6}, {"name": "Acknowledgements", "value": "Professor Sir Richard Doll, Professor Christopher Hudson, Dr Marigold Curling, Dr Eve Wiltshaw, participating hospitals' consultants, nurses and staff, Ann Bateman, Kate Rodriques, Gillian Saunders, Rosalie Thomson, Nina Saroi", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "No explicit conclusion found in the given text.", "mandatory": true, "score": 0.5}, {"name": "No. of subjects", "value": "No explicit no. of subjects found in the given text.", "mandatory": true, "score": 0.3}, {"name": "Relative risk", "value": "No explicit relative risk found in the given text.", "mandatory": true, "score": 0.3}, {"name": "Length of follow", "value": "No explicit length of follow found in the given text.", "mandatory": true, "score": 0.3}]]}, {"name": "Association Between the Frequent Use of Perineal Talcum Powder Products and Ovarian Cancer a Systematic Review and Meta-analysis", "features": [{"features": [{"name": "Conclusion", "value": "This review suggests an increased risk of ovarian cancer associated with frequent perineal powder exposure of 31\u201365%.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "66,876 patients", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "1.47 (95% CI 1.31, 1.65)", "mandatory": true, "score": 0.9}, {"name": "Length of Follow", "value": null, "mandatory": true, "score": 0.3}, {"name": "Publication Quality", "value": "High (median NOS = 8, range: 4 to 9)", "mandatory": false, "score": 0.6}, {"name": "Heterogeneity", "value": "Low heterogeneity (I2= 24%, P=0.22)", "mandatory": false, "score": 0.5}, {"name": "Bias Assessment", "value": "No evidence of bias", "mandatory": false, "score": 0.7}]}, [{"name": "Conclusion", "value": "Frequent perineal exposure to talcum powder is associated with an increased risk of ovarian malignancy.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "6542 ovarian cancer cases and 66,876 women", "mandatory": true, "score": 0.8}, {"name": "Relative Risk", "value": "Adjusted odds ratios and the adjusted hazard ratio were combined given the infrequency of ovarian cancer. The results of the meta-analysis indicate a statistically significant increase in ovarian malignancy when exposed to frequent perineal talcum powder use.", "mandatory": true, "score": 0.9}, {"name": "Length of Follow", "value": "Not specified", "mandatory": true, "score": 0.5}, {"name": "Eligibility Criteria", "value": "The selection process was restricted to observational cohort and case-control study designs. Studies also had to report primary data on frequent, multiple times per week perineal exposure to talc. Other uses of talcum powder were excluded. Study size (n>10 cancers) and defined research methods were also criteria for inclusion.", "mandatory": false, "score": 0.7}, {"name": "Assessment", "value": "The Newcastle Ottawa Scale (NOS) was used to assess the quality of the studies selected for inclusion. A score of 0-3 reflects a very high risk of bias, 4-6 reflects a high risk of bias, and 7-9 reflects a high-quality study with low risk of bias. The scale assesses the criteria used to select study groups, the comparability of study groups, and ascertainment exposure or outcome of interest.", "mandatory": false, "score": 0.6}, {"name": "Data Synthesis", "value": "Individual study results were combined using summary estimates generated from the random effects model and displayed with forest plots. Heterogeneity and publication bias were evaluated. Sensitivity analyses were performed.", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "Frequent perineal talcum powder use is associated with an increased risk of ovarian cancer.", "mandatory": true, "score": 0.95}, {"name": "No. of subjects", "value": "2529", "mandatory": true, "score": 0.9}, {"name": "Relative risk", "value": "1.47", "mandatory": true, "score": 0.85}, {"name": "Length of follow", "value": "N/A", "mandatory": true, "score": 0.8}, {"name": "Publication bias", "value": "None detected", "mandatory": false, "score": 0.7}, {"name": "Age range of included women", "value": "18-79 years", "mandatory": false, "score": 0.6}, {"name": "Median NOS of included case-control studies", "value": "8 out of 9", "mandatory": false, "score": 0.5}, {"name": "Range of frequent talcum powder use", "value": "4-7x per week", "mandatory": false, "score": 0.4}], [{"name": "Conclusion", "value": "Frequent use of perineal talcum powder is associated with an increased risk of ovarian cancer, with a pooled adjusted odds ratio of 1.47 (95% CI 1.31, 1.65).", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": "11 contributing studies", "mandatory": true, "score": 0.8}, {"name": "Relative risk", "value": "1.47 (95% CI 1.31, 1.65)", "mandatory": true, "score": 0.9}, {"name": "Length of follow", "value": "longest published follow-up available from the Nurses\u2019 Health Study cohort", "mandatory": true, "score": 0.7}, {"name": "Type of studies", "value": "Both case-control and cohort observational studies", "mandatory": false, "score": 0.6}, {"name": "Mechanism of carcinogenesis", "value": "Trans-genital migration of talc powder through the fallopian tubes to the ovaries and peritoneum results in inflammation and a cascade of changes that result in carcinogenesis", "mandatory": false, "score": 0.5}, {"name": "Strengths", "value": "Focus on frequent users of perineal talcum powder", "mandatory": false, "score": 0.4}, {"name": "Limitations", "value": "Cohort studies did not define the type of powder exposure, consistently define frequency and duration, capture changes in exposure over time, and relied on recall by participants for exposure which may involve misclassification as would be expected in case control studies", "mandatory": false, "score": 0.4}], [{"name": "Conclusion", "value": "The frequent use of perineal talcum powder use is associated with increased risk of ovarian cancer. These results support women avoiding the frequent use of talcum powder in the perineal area.", "mandatory": true, "score": 0.9}, {"name": "No. of subjects", "value": "Pooled data from 10 case-control studies and a single cohort study were analyzed.", "mandatory": true, "score": 0.8}, {"name": "Relative risk", "value": "The article does not explicitly state the relative risk.", "mandatory": true, "score": 0.5}, {"name": "Length of follow", "value": "The article does not explicitly state the length of follow.", "mandatory": true, "score": 0.5}, {"name": "Limitations", "value": "The article mentions limitations in the construction of selection criteria, variations in the definition of talcum powder use, and the possibility of additional confounders.", "mandatory": false, "score": 0.7}, {"name": "Supplementary Information", "value": "The online version contains supplementary material available at https://doi.org/10.1007/s11606-022-07414-7.", "mandatory": false, "score": 0.6}, {"name": "Acknowledgements", "value": "The article acknowledges the help of Evans Whitaker, MD MLIS and Katie O\u2019Brien, PhD, as well as describes the conflict of interest for Rebecca Smith-Bindman.", "mandatory": false, "score": 0.6}], [{"name": "Conclusion", "value": "Exposure to asbestos and fibrous talc in cosmetic talc powders may cause serous ovarian cancer.", "mandatory": true, "score": 0.9}, {"name": "No. of Subjects", "value": "Not explicitly mentioned", "mandatory": true, "score": 0.5}, {"name": "Relative Risk", "value": "Not explicitly mentioned", "mandatory": true, "score": 0.5}, {"name": "Length of Follow-up", "value": "Not explicitly mentioned", "mandatory": true, "score": 0.5}, {"name": "Source", "value": "J Occup Environ Med 2020; 62(2):e65-e77.", "mandatory": false, "score": 0.8}, {"name": "Publisher's Note", "value": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", "mandatory": false, "score": 0.7}, {"name": "Relevance of Genital Powder Use", "value": "The study examines the evidence on the association between genital powder use and ovarian cancer risk.", "mandatory": false, "score": 0.6}]]}]